Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

Novavax stock was climbing again on Monday after the company expressed new confidence in the eventual approval of its ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

Novavax (NVAX) closed the most recent trading day at $6.41, making no change from the previous trading session. This change lagged the S&P 500's 1.47% gain on the day. At the same time ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...